Practice Point CME

Your Sorted CME/CE Activities

Number of search result: 18

Diagnostic Considerations for Optimizing Successful Outcomes in Hemophagocytic Lymphohistiocytosis

Activity Details

Diagnostic Considerations for Optimizing Successful Outcomes in Hemophagocytic Lymphohistiocytosis

Activity Summary:
Clinical Viewpoints HLH includes a curriculum that highlights the very latest clinical data in Hemophagocytic Lymphohistiocytosis (HLH). Slides are developed and updated throughout the year by leading HLH expert physicians. The Lecture Library offers various topics that can be accessed for AMA or ANCC credit. Review the content and complete the pre- and post-tests and evaluation to receive your credit.

HLH is an aggressive and life-threatening syndrome of excessive immune activation. In persons with HLH, timely diagnosis and appropriate treatment are essential to achieving a successful outcome. This activity will utilize case-based scenarios to review the diverse clinical presentations of suspected HLH, time-efficient approaches for diagnosis, and considerations for targeted treatment and supportive management strategies. Continue to visit the Lecture Library series throughout 2022 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints HLH Planning Committee.

Faculty:Michelle Hermiston, MD, PhD

Accreditation Type:AMA and ANCC

Launch Date:March 30, 2022

Release Date:March 30, 2022

Expiration Date: February 28, 2023

Estimated Time to Complete Activity:1 Hour

ACCESS THIS ACTIVITY

$Hot Topics on Relapsed/Refractory Multiple Myeloma from the 63rd ASH Annual Meeting*$

Hot Topics on Relapsed/Refractory Multiple Myeloma from the 63rd ASH Annual Meeting*

Activity Details

Hot Topics on Relapsed/Refractory Multiple Myeloma from the 63rd ASH Annual Meeting*

Activity Summary:
The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to continual updates from ongoing clinical trials on recently approved and emerging treatment approaches. Clinicians therefore need to stay abreast with recent progress to enable improved outcomes for patients.

This educational Clinical Clip will highlight important advances in RRMM based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting

Faculty:Joseph Mikhael, MD, MEd, FRCPC

Accreditation Type:AMA

Launch Date:December 18, 2021

Release Date:December 18, 2021

Expiration Date: November 30, 2022

Estimated Time to Complete Activity:0.25 hours

ACCESS THIS ACTIVITY

Hot Topics on CAR T- Cell Therapy from the 63rd ASH Annual Meeting*

Activity Details

Hot Topics on CAR T- Cell Therapy from the 63rd ASH Annual Meeting*

Activity Summary:
The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies.

This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Faculty:Michael Wang, MD

Accreditation Type:AMA

Launch Date:December 17, 2021

Release Date:December 17, 2021

Expiration Date: November 30, 2022

Estimated Time to Complete Activity:0.25 hours

ACCESS THIS ACTIVITY

Hot Topics on Low-Risk Myelodysplastic Syndromes (MDS) from the 63rd ASH Annual Meeting*

Activity Details

Hot Topics on Low-Risk Myelodysplastic Syndromes (MDS) from the 63rd ASH Annual Meeting*

Activity Summary:
Clinicians need to keep up with recent progress in low-risk myelodysplastic syndromes (MDS) to facilitate appropriate integration of newly approved and novel therapies

This educational Clinical Clip will highlight key updates in low-risk MDS based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Faculty:Rami Komrokji, MD

Accreditation Type:AMA

Launch Date:December 16, 2021

Release Date:December 16, 2021

Expiration Date: November 30, 2022

Estimated Time to Complete Activity:0.25 hours

ACCESS THIS ACTIVITY

Emerging Therapy Approaches for High-Risk Myelodysplastic Syndromes (MDS) - Conversation 2 of 2

Activity Details

Emerging Therapy Approaches for High-Risk Myelodysplastic Syndromes (MDS) - Conversation 2 of 2

Activity Summary:
Until recently, there has been a lack of treatment options for high-risk MDS. An increased understanding of the genetics and signaling pathways has led to the development of several novel agents and combinations for the treatment of high-risk MDS.

In this activity, Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji will deliberate on the most promising emerging therapies and their potential in improving outcomes for patients with high-risk MDS.

Faculty:Courtney DiNardo, MD, MSCE, Rami Komrokji, MD and Gail Roboz, MD

Accreditation Type:AMA, ANCC and ACPE

Launch Date:December 6, 2021

Release Date:November 30, 2021

Expiration Date: September 30, 2022

Estimated Time to Complete Activity:1 hour

ACCESS THIS ACTIVITY

Updates in High-Risk Myelodysplastic Syndromes (MDS) - Conversation 1 of 2

Activity Details

Updates in High-Risk Myelodysplastic Syndromes (MDS) - Conversation 1 of 2

Activity Summary:
High-risk myelodysplastic syndromes (MDS) pose a challenge in terms of diagnosis, risk stratification, and treatment. Additionally, in recent years, the clinical, molecular, cellular, and immunological factors associated with high-risk MDS have become clearer.

This has led to several updates in the diagnosis and management of high-risk MDS, which will be discussed by Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji. The expert faculty will also review clinical case scenarios to guide participants in integrating recent updates in high-risk MDS.

Faculty:Courtney DiNardo, MD, MSCE, Rami Komrokji, MD and Gail Roboz, MD

Accreditation Type:AMA, ANCC and ACPE

Launch Date:November 22, 2021

Release Date:November 18, 2021

Expiration Date: September 30, 2022

Estimated Time to Complete Activity:1 hour

ACCESS THIS ACTIVITY

Conversations in Hematology/Oncology: Leukemic Transformation of Myelodysplastic Syndromes: Identification, Evaluation and Management Issues

Activity Details

Conversations in Hematology/Oncology: Leukemic Transformation of Myelodysplastic Syndromes: Identification, Evaluation and Management Issues

Activity Summary:

These certified AMA/ANCC/ACPE activities feature a discussion among three experts that will review the current and emerging treatment landscape of high-risk myelodysplastic syndromes (MDS). The program includes two activities that will feature the faculty discussing recent updates in the standard of care for high-risk MDS and what is on the horizon for high-risk MDS.

Faculty:Faculty varies

Accreditation Type:AMA, ANCC and ACPE

Launch Date:

Release Date:

Expiration Date:

Estimated Time to Complete Activity:

ACCESS THIS ACTIVITY

Independent Conference Coverage from the American College of Chest Physicians Annual Meeting 2021*

Activity Details

Independent Conference Coverage from the American College of Chest Physicians Annual Meeting 2021*

Activity Summary:
Pulmonary hypertension due to interstitial lung disease (PH-ILD) is a debilitating condition that has been classified recently. It poses significant challenges for clinical practice in terms of diagnosis and treatment. Updates in the understanding and management of PH-ILD, are hence widely anticipated.

These educational Clinical Clips will highlight important advances in the medical management of patients with PH-ILD on data presented at the American College of Chest Physicians Annual Meeting 2021.

Faculty:Steven Nathan, MD

Accreditation Type:AMA, ANCC and ACPE

Launch Date:October 20, 2021

Release Date:October 20, 2021

Expiration Date: September 30, 2022

Estimated Time to Complete Activity:.5 hours

ACCESS THIS ACTIVITY

Current and Emerging Perspectives in Chronic Immune Thrombocytopenia - Updated 12/14/21

Activity Details

Current and Emerging Perspectives in Chronic Immune Thrombocytopenia - Updated 12/14/21

Activity Summary:
Immune thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to bruising and bleeding. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins (IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP. Since 2008, the approval of thrombopoietin-receptor agonists (TPO-RAs) including a second-generation oral TPO-RA and a spleen tyrosine kinase (Syk) inhibitor, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment. This landscape will be further transformed with a sizable clinical pipeline including inhibitors of CD20, CD40, neonatal Fc receptor (FcRn), bruton’s tyrosine kinase (BTK), and Syk signaling.

This slide kit is designed to keep busy clinicians abreast of the emerging evidence for available treatments and the novel therapy pipeline, to optimize the treatment and care for patients with ITP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Faculty:Hanny Al-Samkari, MD

Accreditation Type:AMA and ANCC

Launch Date:August 30, 2021

Release Date:August 30, 2021

Expiration Date: July 31, 2022

Estimated Time to Complete Activity:1 hour

ACCESS THIS ACTIVITY

Independent Coverage of the 2021 International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

Activity Details

Independent Coverage of the 2021 International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

Activity Summary:
Effective strategies for immune thrombocytopenia (ITP) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with ITP based on data presented at the 2021 International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress.

Faculty:Cindy Neunert, MD, MSCS

Accreditation Type:AMA and ANCC

Launch Date:July 19, 2021

Release Date:July 19, 2021

Expiration Date: June 30, 2022

Estimated Time to Complete Activity:.25 hours per clip

ACCESS THIS ACTIVITY

Independent Coverage of the 2021 European Hematology Association (EHA) Virtual Congress*

Activity Details

Independent Coverage of the 2021 European Hematology Association (EHA) Virtual Congress*

Activity Summary:
Effective strategies for immune thrombocytopenia (ITP) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with ITP based on data presented at the 2021 European Hematology Association (EHA) Virtual Congress.

Faculty:James Bussel, MD

Accreditation Type:AMA and ANCC

Launch Date:June 11, 2021

Release Date:June 11, 2021

Expiration Date: May 31, 2022

Estimated Time to Complete Activity:.25 hours per clip

ACCESS THIS ACTIVITY

Case-Based Strategies to Improve Diagnosis and Treatment of PH-ILD - Updated 11/01/2021

Activity Details

Case-Based Strategies to Improve Diagnosis and Treatment of PH-ILD - Updated 11/01/2021

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease. Slides are developed and updated throughout the year by leading pulmonology expert physicians. Continue to visit the Lecture Library series throughout 2021 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

This activity is comprised of two clinical case scenarios to illustrate best-practice recommendations for diagnosis and further treatment and management of patients presenting with PH-ILD. The slides will provide guidance on safely and effectively integrating recent updates and evidence in PH-ILD into clinical practice.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Faculty:Christopher King, MD

Accreditation Type:Expired Activity

Launch Date:March 24, 2021

Release Date:March 10, 2021

Expiration Date: February 28, 2022

Estimated Time to Complete Activity:Expired Activity

ACCESS THIS ACTIVITY

Conversations in Oncology: Updates in the Treatment of Graft Versus Host Disease

Activity Details

Conversations in Oncology: Updates in the Treatment of Graft Versus Host Disease

Activity Summary:
This certified CME/CNE activity features a recorded discussion among three experts reviewing new therapies and protocols to improve outcomes in (Graft Versus Host Disease) GVHD.

This educational activity will focus on the new therapies and protocols to improve outcomes in GVHD. Data will be reviewed and analyzed by expert faculty while discussing common patient scenarios and best practices in treatment.

Faculty:James Ferrara, MD, Mark A. Schroeder, MD and Celalettin Ustun, MD

Accreditation Type:Expired Activity

Launch Date:March 16, 2021

Release Date:March 16, 2021

Expiration Date: February 28, 2022

Estimated Time to Complete Activity:Expired Activity

ACCESS THIS ACTIVITY

Emerging Considerations in the Management of PH-ILD - Updated 11/01/2021

Activity Details

Emerging Considerations in the Management of PH-ILD - Updated 11/01/2021

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease. Slides are developed and updated throughout the year by leading pulmonology expert physicians. Continue to visit the Lecture Library series throughout 2021 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

This activity is designed to provide an overview of the diagnosis, treatment, and management of patients presenting with PH-ILD. Latest evidence from completed and ongoing clinical trials will be presented to identify therapeutic approaches useful in reducing the symptom burden of afflicted patients. Current treatment paradigms, their limitations, and new developments in PH-ILD will also be discussed.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Faculty:Steven Nathan, MD

Accreditation Type:Expired Activity

Launch Date:March 10, 2021

Release Date:March 10, 2021

Expiration Date: February 28, 2022

Estimated Time to Complete Activity:Expired Activity

ACCESS THIS ACTIVITY

Clinical Viewpoints PH-ILD Lecture Library

Activity Details

Clinical Viewpoints PH-ILD Lecture Library

Faculty:Various Faculty

Accreditation Type:AMA, ANCC and ACPE

Launch Date:

Release Date:

Expiration Date:

Estimated Time to Complete Activity:1 Hour per Module

ACCESS THIS ACTIVITY

Advances in the Clinical Management of Hereditary Angioedema <br />Standard of Care, New and Emerging Therapies, Patient-Centered Care & Shared Decision-making - Updated 5/27/21

Activity Details

Advances in the Clinical Management of Hereditary Angioedema <br />Standard of Care, New and Emerging Therapies, Patient-Centered Care & Shared Decision-making - Updated 5/27/21

Activity Summary:
The Clinical Viewpoints Hereditary Angioedema lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slides developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

The field of hereditary angioedema (HAE) has recently evolved with the advent of new and forthcoming diagnostic and treatment measures. In particular, the shift toward oral medications will most certainly improve the quality of life for HAE patients. This lecture provides an overview of current diagnostic and treatment procedures recommended by the World Allergy Organization (WAO) and the United States Hereditary Angioedema Association Medical Advisory Board (US HAEA MAB) and summarizes forthcoming new advances in the field of HAE.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Faculty:Marc Riedl, MD, MS

Accreditation Type:Expired Activity

Launch Date:February 16, 2021

Release Date:February 10, 2021

Expiration Date: January 31, 2022

Estimated Time to Complete Activity:Expired Activity

ACCESS THIS ACTIVITY

CONVERSATIONS IN HEMATOLOGY / ONCOLOGY: Clinical Focus on Myeloproliferative Neoplasms (MPNs)

Activity Details

CONVERSATIONS IN HEMATOLOGY / ONCOLOGY: Clinical Focus on Myeloproliferative Neoplasms (MPNs)

Activity Summary:

This certified CME/CNE activity features a recorded discussion among three experts that reviews the latest research and options for the management of patients with MPNs.

This activity will feature Dr. Srdan Verstovsek, Dr. Ruben Mesa and Dr. John Mascarenhas discussing the standard of care for Polycythemia Vera and Myelofibrosis. The discussion will be supplemented by slides based on key discussion points which are available for download.

Faculty:Srdan Verstovsek, MD, Ruben A. Mesa, MD and John Mascarenhas, MD

Accreditation Type:Expired Activity

Launch Date:February 10, 2021

Release Date:February 10, 2021

Expiration Date: January 31, 2022

Estimated Time to Complete Activity:Expired Activity

ACCESS THIS ACTIVITY

Case-based Treatment Strategies in Patients with Chronic Immune Thrombocytopenia

Activity Details

Case-based Treatment Strategies in Patients with Chronic Immune Thrombocytopenia

Activity Summary:
Treatment choices for chronic immune thrombocytopenia (ITP) are complicated by the heterogeneity of the disease and the inability not only to diagnose it but also to objectively predict patient responses to treatment and outcomes. With lack of head-to-head clinical trial comparisons to guide therapeutic options and sequencing of treatment strategies, as well as the development of emerging agents, expert opinion is critical in guiding clinical decision-making. Furthermore, ITP in the elderly and pregnant patient poses considerable challenges, so specific individualized management strategies ideally should be considered to optimize outcomes.

Using patient case studies, James Bussel, MD and Hanny Al-Samkari, MD discuss real-life management of patients with chronic ITP.

Faculty:James Bussel, MD and Hanny Al-Samkari, MD

Accreditation Type:Expired Activity

Launch Date:December 2, 2020

Release Date:November 10, 2020

Expiration Date: October 31, 2021

Estimated Time to Complete Activity:Expired Activity

ACCESS THIS ACTIVITY

CME/CE Activity Sorter
(Select therapeutic category and activity type of interest and view your sorted activities below)

Your Sorted CME/CE Activities

Diagnostic Considerations for Optimizing Successful Outcomes in Hemophagocytic Lymphohistiocytosis

Hot Topics on Relapsed/Refractory Multiple Myeloma from the 63rd ASH Annual Meeting*

Hot Topics on CAR T- Cell Therapy from the 63rd ASH Annual Meeting*

Hot Topics on Low-Risk Myelodysplastic Syndromes (MDS) from the 63rd ASH Annual Meeting*

Emerging Therapy Approaches for High-Risk Myelodysplastic Syndromes (MDS) - Conversation 2 of 2

Updates in High-Risk Myelodysplastic Syndromes (MDS) - Conversation 1 of 2

Conversations in Hematology/Oncology: Leukemic Transformation of Myelodysplastic Syndromes: Identification, Evaluation and Management Issues

Independent Conference Coverage from the American College of Chest Physicians Annual Meeting 2021*

Current and Emerging Perspectives in Chronic Immune Thrombocytopenia - Updated 12/14/21

Independent Coverage of the 2021 International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

Independent Coverage of the 2021 European Hematology Association (EHA) Virtual Congress*

Case-Based Strategies to Improve Diagnosis and Treatment of PH-ILD - Updated 11/01/2021

Conversations in Oncology: Updates in the Treatment of Graft Versus Host Disease

Emerging Considerations in the Management of PH-ILD - Updated 11/01/2021

Clinical Viewpoints PH-ILD Lecture Library

Advances in the Clinical Management of Hereditary Angioedema <br />Standard of Care, New and Emerging Therapies, Patient-Centered Care & Shared Decision-making - Updated 5/27/21

CONVERSATIONS IN HEMATOLOGY / ONCOLOGY: Clinical Focus on Myeloproliferative Neoplasms (MPNs)

Case-based Treatment Strategies in Patients with Chronic Immune Thrombocytopenia